Why was the amivantamab (Rybrevant) + lazertinib (Leclaza) + chemotherapy arm not presented in the Mariposa‑2 trial results for EGFR‑mutated non‑small‑cell lung cancer patients who progressed on prior EGFR‑TKI therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 12, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Why the Amivantamab + Lazertinib + Chemotherapy Arm Was Not Presented as a Recommended Option in MARIPOSA-2

The quadruplet regimen of amivantamab + lazertinib + chemotherapy was not recommended due to excessive hematological toxicities (52% serious treatment-emergent adverse events) that necessitated a protocol modification to delay lazertinib initiation until after carboplatin completion, combined with no demonstrated overall survival benefit over chemotherapy alone. 1

The Safety Profile That Led to Protocol Changes

The MARIPOSA-2 trial enrolled 657 patients post-osimertinib progression and randomized them 2:2:1 to three arms: chemotherapy alone, amivantamab + chemotherapy, and amivantamab + lazertinib + chemotherapy. 1

Excessive Hematological Toxicity in the Quadruplet Arm

  • The amivantamab + lazertinib + chemotherapy arm demonstrated excessive hematological toxicities that were clinically unacceptable, with 52% of patients experiencing serious treatment-emergent adverse events compared to 32% with amivantamab + chemotherapy and only 20% with chemotherapy alone. 1

  • This toxicity profile necessitated a regimen change during the trial itself, requiring lazertinib to be started only upon completion of carboplatin rather than concurrently, indicating the combination was too toxic as originally designed. 1

  • The quadruplet regimen required longer follow-up to better understand its risk-to-benefit profile, suggesting the safety concerns were significant enough to prevent immediate clinical adoption. 1

Efficacy Did Not Justify the Toxicity

PFS Benefit Without OS Improvement

  • While the quadruplet arm achieved a median PFS of 8.3 months (HR 0.44 vs chemotherapy alone at 4.2 months), overall survival results remained premature with no demonstrated OS benefit between any of the arms. 1

  • The amivantamab + chemotherapy doublet achieved a PFS of 6.3 months (HR 0.48), which was only 2 months shorter than the quadruplet but with substantially better tolerability (32% vs 52% serious adverse events). 1

  • ASCO guidelines explicitly note that both MARIPOSA-2 and ATTLAS demonstrated improvement in PFS but not OS compared with platinum chemotherapy alone, with significantly increased toxicity including serious adverse events. 1

The Clinical Recommendation That Emerged

ASCO Guideline Position

ASCO recommends platinum-based chemotherapy with or without amivantamab (the triplet, not quadruplet) for patients with progressive disease on osimertinib or other EGFR TKIs without emergent T790M or other targetable alterations (Evidence quality: Moderate; Strength of recommendation: Strong). 1

  • The guideline panel specifically recommends that platinum-doublet chemotherapy be offered for most patients who experience progression after osimertinib, given the lack of OS difference and increased toxicity profiles seen with intensified regimens. 1

  • The amivantamab + chemotherapy triplet regimen offers an evidence-based, potentially more effective approach versus doublet chemotherapy alone, but the added adverse event profile needs to be considered on an individual basis. 1

Why the Triplet Was Preferred Over the Quadruplet

  • The triplet (amivantamab + chemotherapy) achieved clinically meaningful PFS improvement (HR 0.48) with a more manageable toxicity profile compared to the quadruplet's marginal additional PFS benefit at the cost of substantially worse hematological toxicity. 1

  • The objective response rates were essentially identical between the triplet and quadruplet arms (64% vs 63%), providing no additional efficacy justification for the increased toxicity. 1

Critical Pitfalls to Avoid

  • Do not assume that adding more agents automatically improves outcomes—the MARIPOSA-2 quadruplet arm demonstrates that excessive toxicity can outweigh modest PFS gains, particularly when OS is not improved. 1

  • Do not overlook the need for protocol modifications during a trial as a red flag—the fact that lazertinib timing had to be changed mid-study due to toxicity signals fundamental tolerability issues with the regimen. 1

  • Recognize that serious adverse events requiring hospitalization or intensive management (52% in the quadruplet arm) directly impact quality of life and may negate any progression-free survival benefit in the absence of overall survival improvement. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.